Description: A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors
Mechanism of Action: REGN 7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in combination with PD1 inhibitor Cemiplimab
Target Patient Population: All Solid Tumors.
Study Design: Drug is administered IV every 3 weeks. First patient in each cohort will be inpatient for observation for either 24 or 48 hours.